To include your compound in the COVID-19 Resource Center, submit it here.

CATT's out of the bag

NIH's National Eye Institute reported that intravitreal Avastin bevacizumab was non-inferior to Lucentis ranibizumab in the Phase III CATT trial to treat wet age-related macular degeneration (AMD). Avastin was non-inferior to Lucentis on the primary endpoint of

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers